Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/ hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: Pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials

Clinical Therapeutics

Volumn 27, Issue 11, 2005, Pages 1795-1805

  Lacourcière, Yves ^a   Neutel, Joel M ^b   Schumacher, Helmut ^c  

^a LAVAL UNIVERSITY   (Canada)

^b Orange County Research Center   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Ambulatory blood pressure monitoring; Angiotensin II receptorblockade; Fixed dose combination; Hydrochlorothiazide; Hypertension; Losartan; Telmisartan

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DELIRIUM; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NAUSEA; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPHYGMOMANOMETRY; STRESS; SWELLING; SYSTOLIC BLOOD PRESSURE; VOMITING;

EID: 29144442424     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.11.014     Document Type: Article

References (30)

1. Kearney P.M., Whelton M., and Reynolds K. Global burden of hypertension: Analysis of worldwide data Lancet 365 2005 217 223
2. Erdine S., and Aran S.N. Current status of hypertension control around the world Clin Exp Hypertens 26 2004 731 738
3. [published correction appears in Jama. 2003;290:197] Chobanian A.V., Bakris G.L., Black H.R. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report Jama 289 2003 2560 2572
4. Wetzels G.E., Nelemans P., Schouten J.S., and Prins M.H. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: A systematic review J Hypertens 22 2004 1849 1855
5. Chobanian A.V., Bakris G.L., Black H.R. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, The National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
6. [published corrections appear in J Hypertens. 2003;21: 2203-2204 and J Hypertens. 2004;22:435] European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 2003 1011 1053
7. [published correction appears in Arch Intern Med. 2004;164:1832] Gluckman T.J., Baranowski B., and Ashen M.D. A practical and evidence-based approach to cardiovascular disease risk reduction Arch Intern Med 164 2004 1490 1500
8. Marcia G., and Parati G. Ambulatory blood pressure monitoring and organ damage Hypertension 36 2000 894 900
9. White W.B. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate Blood Press Monit 6 2001 63 72
10. Verdecchia P., Schillaci G., and Porcellati C. Dippers versus non-dippers J Hypertens Suppl 9 1991 S42 S44
11. Kario K., Pickering T.G., and Umeda Y. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study Circulation 107 2003 1401 1406
12. Ogden L.G., He J., Lydick E., and Whelton P.K. Long-term absolute benefit of lowering blood pressure in hyper tensive patients according to the JNC VI risk stratification Hypertension 35 2000 539 543
13. Gradman A.H., and Acevedo C. Evolving strategies for the use of combination therapy in hypertension Curr Hypertens Rep 4 2002 343 349
14. discussion 95S-100S Moser M., and Black H.R. The role of combination therapy in the treatment of hypertension Am J Hypertens 11 1998 735 785
15. Sapienza S., Sacco P., and Floyd K. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting Clin Ther 57 2003 273 279
16. Hurairah H., and Ferro A. The role of the endothelium in the control of vascular function Int J Clin Pract 58 2004 173 183
17. Pourdjabbar A., Lapointe N., and Rouleau J.L. Angiotensin receptor blockers: Powerful evidence with cardiovascular outcomes? Cant Cardiol 18 Suppl A 2002 7A 14A
18. Neutel J.M., and Lacourciere Y. Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension Hypertens Res 28 2005 555 563
19. White W.B. Relevance of blood pressure variation in the circadian onset of cardiovascular events J Hypertens 57 2003 273 279
20. Sharpe M., Jarvis B., and Goa K.L. Telmisartan: A review of its use in hypertension Drugs 61 2001 1501 1529
21. Pickering T.G., Hall J.E., and Appel L.J. Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research Hypertension 45 2005 142 161
22. Smith D.H., Neutel J.M., Lacourciere Y., and Kempthorne-Rawson J. Prospective, randomized, open-label, blinded endpoint (PROBE) designed trials yield the same results as doubleblind, placebo-controlled trials withrespect to ABPM measurements J Hypertens 21 2003 1291 1298
23. White W.B. Relevance of blood pressure variation in the circadian onset of cardiovascular events J Hypertens Suppl 21 2003 S9 S15
24. Sharpe M., Jarvis B., and Goa K.L. Telmisartan: A review of its use in hypertension Drugs 61 2001 1501 1529
25. Lo M.W., Goldberg M.R., and McCrea J.B. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans Clin Pharmacol Ther 58 1995 641 649
26. McGill J.B., and Reilly P.A. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial Clin Ther 23 2001 833 850
27. Lacourciere Y., and Poirier L. Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects withambulatory systolic hypertension Am J Hypertens 16 2003 1036 1042
28. [published correction appears in Lancet. 2003; 361:1060] Lewington S., Clarke R., Qizilbash N. Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospectivestudies Lancet 360 2002 1903 1913
29. [published correction appears in Jama. 2002;288:2976] ALLHAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Jama 283 2000 1967 1975
30. Siragy H.M. Angiotensin receptor blockers: How important is selectivity? Am J Hypertens 15 2002 1006 1014